May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. announced that it has expanded the company’s focus beyond structural heart disease into cardiovascular (CV) disease, starting with atrial fibrillation (AF).
There are an estimated 126 million adults affected by CV disease in the U.S.i The burden of CV disease is only continuing to increase, leaving hospital systems with tens of thousands of patients to manage. AF, a significant contributor of CV disease, is expected to grow to more than 12 million cases annually in the U.S. by 2030ii, and can result in stroke, heart failure (HF) and even death.
egnite’s expansion into CV disease is driven by an urgent need to improve the quality of care for every CV patient in the U.S. The company’s decision to focus on AF first is based on an early analysis of over 154,000 patients with the condition across six institutions from egnite’s proprietary database, which observed:
- 52% of potentially eligible patients with AF and an elevated risk of stroke were not prescribed anticoagulation.
- 10% increase in 3-year survival rates observed for patients receiving anticoagulation.
“Our vision is to identify and improve the quality of care for every cardiovascular patient in the U.S.,” said Joel Portice, president and chief executive officer of egnite. “To achieve this expansive goal, we are focused on delivering meaningful solutions that advance the cardiovascular health of our society and elevate the role of data and digital technology in critical healthcare decisions.”
egnite’s CardioCare platform will now expand beyond VHD and HF to include AF, acting as a hospital’s single-source solution to help hospitals prioritize care and resources, so they can better identify patients who could benefit from guideline-directed therapy.
“We are seeing more and more atrial fibrillation patients with an elevated risk of stroke. While clinicians already have several therapeutic options for stroke prevention, egnite’s expansion into cardiovascular disease now offers physicians artificial intelligence tools to identify their atrial fibrillation patient population in need of anticoagulation treatment based on their risk of stroke,” said Glenn Barnhart, M.D., chief medical officer of egnite. “As we continue to focus on delivering meaningful improvements in structural heart patient care, we’re excited about the potential of the CardioCare program to become the new standard for how we manage cardiovascular patients more broadly.”
Since egnite’s VHD prevalence abstract, two more manuscripts have been accepted and are in press in Intelligence Based Medicine leveraging over 1 million echocardiograms from egnite’s de-identified database. egnite is using this data to transform healthcare delivery.
For more information: www.egnitehealth.com
i Virani SS, Alonso A, Aparicio HJ, et al.; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950
ii Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063. Epub 2013 Jul 4. PMID: 23831166.